Physician profile
Ronald V Trout
NPI 1194701607
$3,597.15
in general payments reported to CMS, 2019-2025
23 companies · $90.00 in 2025
The $90.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $380 · 2021: $1,845 · 2022: $984 · 2023: $15.85 · 2025: $90.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,227.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $438.80 | 2019-2022 | |
| Abbvie INC. | $323.33 | 2021-2022 | |
| Novo Nordisk INC | $312.06 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $149.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $141.74 | 2019-2022 | |
| Lilly USA, LLC | $135.26 | 2020-2022 | |
| Pfizer INC. | $129.28 | 2019-2022 | |
| Dexcom, INC. | $118.25 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $104.17 | 2019-2022 | |
| Amarin Pharma, INC. | $89.57 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.60 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.09 | 2022 | |
| Eisai INC. | $53.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.37 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.41 | 2019-2022 | |
| Abbott Laboratories | $29.00 | 2021-2022 | |
| Esperion Therapeutics, INC. | $20.23 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.16 | 2021 | |
| Sanofi Pasteur INC. | $16.30 | 2019 | |
| Astellas Pharma US INC | $16.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.11 | 2022 | |
| Grt US Holding, INC. | $14.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Trout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.